Health Condition 1: null- Hyperlipidemic
Conditions
Interventions
Intervention1: EPA A: Eicosapentaenoic acid: 500 mg daily three doses for 3 months
Intervention2: EPA B: EPA + Flucoxanthin
Eicosapentaenoic acid and Flucoxanthin: 500 mg daily three doses for three m
Sponsors
Parry Neutraceuticals
Eligibility
Inclusion criteria
Inclusion criteria: Adult male and female subjects between 18 and 50 yrs (both years inclusive) Willingness to provide written informed consent to participate in the study Understanding the nature and purpose of the study and willing to comply with study procedures Abdominal girth of more than or equal to 102 cm Serum triglycerides equal to or greater than 150 mg/dL and HDL cholesterol Less than 40 mg/dL Negative for HIV 1 & 2, Hepatitis B & C
Exclusion criteria
Exclusion criteria: Subjects not capable of understanding the informed consent Subjects who are on lipid lowering treatment including Statins, fibrates, etc or who are in need of lipid lowering treatment. Subjects with significant hyperglycemia and / or systemic hypertension with related complications including, renal, hepatic, retinal, cardiac, cerebral disorders. Obesity because of identified etiologies such as Cushingâ??s syndrome, hypothyroidism, etc. On a treatment regimen that includes metformin or glitazones
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the study is to evaluate Safety of EPA in adult human male and female subjects with abdominal obesity.Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective of the study is to determine the Effiacay of EPA in adult human male and female subjects with abdominal obesity.Timepoint: 3 month | — |
Countries
India
Contacts
Public ContactDr Devesh Kumar
Project Manager
Outcome results
None listed